Adaptimmune Therapeutics plc American (ADAP) Total Assets by Year
Adaptimmune Therapeutics plc American closed fiscal year 2024 with $246.0M in total assets, $234.1M in total liabilities and $11.8M in shareholder equity. This represents a decrease of 13.0% from the prior fiscal year. The table below carries 12 fiscal years, from 2013 to 2024, and the quarters Adaptimmune Therapeutics plc American has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ADAP Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $246.0M-13.0% | $282.6M-14.1% | $328.9M-30.0% | $469.5M+4.1% | $451.1M+148.5% | $181.5M-34.4% | $276.7M-1.6% | $281.1M+19.9% | $234.5M-22.0% | $300.7M+439.4% | $55.7M | N/A |
| Total Liabilities | $234.1M-3.7% | $243.1M-1.6% | $247.0M-6.3% | $263.6M+139.8% | $109.9M+89.8% | $57.9M+94.0% | $29.9M-61.8% | $78.2M+14.3% | $68.4M+64.2% | $41.6M-21.1% | $52.8M | N/A |
| Total Equity | $11.8M-70.0% | $39.5M-51.7% | $81.9M-60.2% | $206.0M-39.6% | $341.2M+176.0% | $123.6M-49.9% | $246.9M+21.6% | $203.0M+22.2% | $166.1M-35.9% | $259.0M+8659.0% | $3.0M+237.2% | -$2.2M |
ADAP Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2510-Q | Q1'25 | Q4'2410-Q | Q3'24 | Q2'2410-Q | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $130.6M-59.4% | $158.1M-38.7% | $246.0M-13.0% | $317.4M+7.0% | $321.7M-6.2% | $258.0M-10.4% | $282.6M-14.1% | $296.6M-10.7% | $343.0M-11.7% | $288.1M-31.4% | $328.9M-30.0% | $332.2M-6.0% |
| Total Liabilities | $201.6M-10.6% | $195.5M-16.3% | $234.1M-3.7% | $237.4M+13.9% | $225.4M+4.2% | $233.6M+14.4% | $243.1M-1.6% | $208.5M-4.7% | $216.3M-12.2% | $204.2M-20.4% | $247.0M-6.3% | $218.9M+94.5% |
| Total Equity | -$71.0M-173.7% | -$37.4M-253.6% | $11.8M-70.0% | $80.0M-9.2% | $96.3M-24.0% | $24.4M-70.9% | $39.5M-51.7% | $88.1M-22.2% | $126.7M-10.8% | $83.9M-48.6% | $81.9M-60.2% | $113.3M-53.0% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Adaptimmune Therapeutics plc American financials
Frequently Asked Questions
What was Adaptimmune Therapeutics plc American's total assets in fiscal year 2024?
Adaptimmune Therapeutics plc American closed fiscal year 2024 with $246.0M in total assets, $234.1M in total liabilities and $11.8M in shareholder equity.
How fast is Adaptimmune Therapeutics plc American's total assets growing?
Adaptimmune Therapeutics plc American (ADAP) total assets fell by 13.0% year over year, from $282.6M to $246.0M in fiscal year 2024.
What was Adaptimmune Therapeutics plc American's total assets in the most recent quarter?
Adaptimmune Therapeutics plc American (ADAP) reported $130.6M in total assets in Q2 2025. This represents a decrease of 59.4% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Adaptimmune Therapeutics plc American (ADAP) reported on that line in every period on record.